Exxel Pharma Inc. (EXXL)

Chart not available yet

Data will show when the stock starts trading.

Market Cap	n/a
Revenue (ttm)	225,000 +125.0%
Net Income	-1.27M
EPS	-0.16
Shares Out	7.99M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About EXXL

Exxel Pharma Inc. is a biopharmaceutical company focused on developing novel therapeutics for the treatment of neuronal hypersensitivity disorders. We are developing EX937, our lead product candidate, for refractory chronic cough (RCC) and other hypersensitivity disorders that share the pathophysiology of hypersensitized sensory neurons. Investigational New Drug enabling studies supporting our early clinical development program (ERCP) have been completed and we target the first-in-human (FIH) dosing in 2026, pending capitalization and completio...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Employees: 1
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: EXXL
• Website: https://exxelpharma.com/

Financial Performance

Data Source: SEC filings Last updated: Aug 20, 2026

The data for this page was gathered manually by the Stock Analysis team, from official company filings available on SEC.gov.

Data Sources Report a data error